Results 71 to 80 of about 21,933 (136)

Effect of astaxanthin in imatinib mesylate-induced cardiotoxicity

Acta Medica Alanya, 2020
Aim: Imatinib mesylate is a tyrosine kinase inhibitor and is approved as a standard first-line therapy of chronic myeloid leukemia. Oxidative stress, as well as intracellular calcium overload and mitochondrial dysfunction, play an important role in ...
İshak Suat Övey, Can Ramazan Öncel
doaj  

Imatinib resistance: diagnostic and therapeutic choices

Clinical Management Issues, 2015
We report a case of a 42-year-old woman with t(9;22) positive chronic myeloid leukemia (CML) who developed a sub-optimal response to therapy with imatinib mesylate due to M351T mutation and low plasma level of imatinib. Dose increase of imatinib resulted
Marianna De Muro, Odoardo Maria Olimpieri, Rosa Greco, Lidia Altomare   +3 more
doaj   +1 more source

Diabetic Atrial Cardiomyopathy: Pathogenesis, Diagnosis, Management, AI‐Driven Diagnosis, and Risk Prediction

Journal of Diabetes Research, Volume 2026, Issue 1, 2026.
Background Diabetic atrial cardiomyopathy, a component of diabetic cardiomyopathy, is increasingly recognized. However, atrial‐focused mechanistic and clinical frameworks remain less developed than ventricular paradigms. Main Body This review synthesizes the pathogenesis of diabetic atrial cardiomyopathy from conventional, multiomics, and translational
Helin Yang, Kexiao Yu, Bing Liang, Zhipeng Tao   +3 more
wiley   +1 more source

High Shear Stress‐Induced Endothelial Piezo1 Downregulation Promotes Intracranial Aneurysm Formation via the PDGF‐BB/PDGFRβ Paracrine Signaling Pathway

CNS Neuroscience &Therapeutics, Volume 31, Issue 12, December 2025.
HSS downregulates Piezo1 expression in ECs, which subsequently enhances PDGF‐BB expression through the YAP/β‐catenin signaling pathway. The elevated PDGF‐BB facilitates phenotypic transition of VSMCs via PDGFRβ binding, ultimately contributing to IA formation.
Zhiwen Lu, Sisi Li, Fengfeng Xu, Haishuang Tang, Shijie Zhu, Chuanchuan Wang, Xiaohua Yang, Qinghai Huang   +7 more
wiley   +1 more source

Imatinib and hypophosphatemia: Case report and review of literature

Journal of Oncological Sciences, 2017
Imatinib mesylate is a potent inhibitor of the BCR-Abl kinases, c-Kit, PDGFR, and fms. Imatinib used for treatment of chronic myeloid leukemia and gastrointestinal stromal tumor. Imatinib has been well tolerated.
Erdem Şen, İrem Öner, Özlem Ata
doaj   +1 more source

A tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lens

Cancer, Volume 131, Issue 21, 1 November 2025.
ABSTRACT Advances in the prognostication, monitoring, and treatment of both the acute and chronic leukemias have led to drastically improved outcomes over the past 2 decades. With the advent of targeted therapies, including antibodies such as blinatumomab and inotuzumab and small molecule inhibitors, such as the BCR::ABL1 tyrosine kinase inhibitors ...
Hagop M. Kantarjian, Gautam Borthakur, Naval Daver, Courtney DiNardo, Guillermo Garcia‐Manero, Ghayas Issa, Elias Jabbour, Nitin Jain, Tapan Kadia, Sanam Loghavi, Farhad Ravandi, Guilin Tang, Mary Alma Welch, William Wierda   +13 more
wiley   +1 more source

Detection of BCR-ABL kinase domain mutations in CD34+ cells from newly diagnosed chronic phase CML patients and their association with imatinib resistance [PDF]

, 2011
BCR-ABL kinase domain (KD) mutations, the most common cause of imatinib resistance, are infrequently detected in newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML) patients.
Riaz ul-Haq, Abdul Qayyum, Mubashar Naqvi, Tariq Gill, Muhammad Khalid, Ammara Tahir, Abid Jamil, Ahmad Khalid, Mahwish Khan, Muhammad Ferhan, Ijaz Shah, Abid Taj, Weng Qin, Mudassar Iqbal, Muhammad Abbad, Aamer Aleem, Tanveer Akhtar, Zafar Iqbal, Najeeb ur-Rehman, Shahid Baig   +19 more
core  

Six years survival on imatinib with no disease progression after diagnosis of metastatic duodenal gastrointestinal stromal tumour: a case report [PDF]

, 2008
Introduction: A duodenal Gastrointestinal Stromal Tumour (GIST) is a rare finding and until recently advanced disease had a poor prognosis. A PubMed search revealed no reports of more than five years survival of inoperable GIST on chemotherapy with WHO ...
Morrissey, John R., Bhattacharya Sayantan, Morrissey John, Choudhury Amit, Bhattacharya, Sayantan, Ravi, Srinivasan, Mathew, G. (George), Ravi Srinivasan, Mathew George, Choudhury, Amit Kumar   +9 more
core   +1 more source

The teratogenic effects of imatinib mesylate on rat fetuses

Toxicology Reports, 2015
Imatinib mesylate, a selective tyrosine kinase inhibitor, is the first line treatment against chronic myelogenous leukemia and gastrointestinal stromal tumors.
M.M. El Gendy, A.M. Kandil, M.A. Helal, F.M. Zahou   +3 more
doaj   +1 more source

Imatinib Mesylate: Past Successes and Future Challenges in the Treatment of Gastrointestinal Stromal Tumors

, 2011
Just over a decade ago, gastrointestinal tumours were a poorly understood mesenchymal neoplasm unsuccessfully treated with chemotherapy. Cytotoxic therapy for advanced disease yielded response rates of 10% and median survival of just 18 months.
Doran Ksienski
core   +1 more source